DONATE

Bioengineering in reproductive health

Samuel Ojosnegros Martos
Head of Bioengineering in Reproductive Health

ABOUT

Our lab’s focus is on understanding the mechanisms that control mammalian embryo implantation and apply that knowledge to provide solutions that improve human assisted reproduction techniques (ART).

The embryonic development of humans (and mammals in general) requires the implantation of the embryo into the walls of the maternal uterus. This process is highly inefficient as on average, 25–30% of conceptions lead to successful live births and around 60% of all conceptions are lost at the time of (or soon after) implantation. However, despite the central role of implantation in human fertility, the process is still elusive to experimentation because of its inaccessibility.

To overcome the elusiveness of this process, the group combines imaging and bioengineering methods to efficiently culture and image pre-implantation embryos and allow them to implant outside the uterus in highly physiological conditions.  Our systems are accessible to imaging tools which allow us to interrogate the genetics, metabolomics, and mechanics of the embryo in a high throughput manner. Using our systems, we are capable to (i) improve embryo culture conditions and (ii) diagnose embryos with improved implantation potential.

Label-free microscopy and multi/hyperspectral imaging

Label-free Microscopy: This technique allows for analyzing cells in their native condition, i.e. without being labeled or altered in any way, by means of retrieving cells autofluorescence signals and thus providing essential metabolic information about living tissues. Combined with multispectral methods, we delve deep into the metabolic complexity of embryos and oocytes, revealing insights previously unattainable.

Hyperspectral Imaging: Our groundbreaking approach employs hyperspectral imaging to obtain the metabolic profiles of embryos and oocytes. This methodology allows us to identify key characteristics at the metabolic level, invisible to conventional techniques like brightfield imaging, offering a unique window into fundamental biological processes.

Hardware Techniques: We have extensive expertise in a variety of advanced microscopy techniques, including two-photon microscopy, laser scanning confocal microscopy, spinning disk confocal microscopy and light-sheet microscopy. The integration of these techniques with multi/hyperspectral detection methods enables us to observe biological samples of interest at cellular level with spectral characteristics.

AI and Software Analysis: We employ sophisticated data analysis tools such as spectral histogram analysis and phasor-plot analysis combined with artificial intelligence (AI) methods for classification. These techniques allow us to interpret complex multi/hyperspectral data and draw meaningful conclusions about the viability and quality of embryos and oocytes.

4D (x, y, z, and λ) Hyperspectral Autofluorescent Images of Mouse Oocytes and Blastocysts. The samples were imaged using a Zeiss LSM780 inverted microscope with a C-Apochromat 40x/1.20 W Korr Zeiss objective. The imaging conditions were maintained at 37°C and 5% CO2. A Mai-Tai DeepSee laser provided two-photon excitation at a wavelength λex = 780nm. The emitted autofluorescence spanned from 410 nm to 695 nm and was collected by a 32-channel PMT GaAsP spectral detector. The image captures multiple planes, separated by 2.5μm and 5μm steps for oocytes and embryos respectivelly. The pseudo-color representation of the hyperspectral images was achieved using additive blending to integrate the 32 channel colors for each pixel.

Bioengineering to improve embryo implantation

We have developed proprietary 3D ex vivo hydrogel-based implantation platforms which mimic the uterine microenvironment, allowing the embryo to progress towards post-implantation stages in an amenable way for optical microscopy. Working towards obtaining dynamic control of embryo culture, we have integrated our hydrogels in a microfluidic device allowing for controlled nutrient supply, oxygen concentration and long-term embryo culture. Our 3D ex vivo hydrogel-based implantation platforms allow for drug screening and determination of its impact on embryo implantation and development.

We use our 3D ex vivo implantation platform to understand embryo implantation with a focus on the biomechanics of the system. To this means we quantify the displacement of the matrix generated by the embryos using PIV or DVC algorithms. We look at the forces and resulting patterns embryos are applying in order to penetrate the hydrogel and also how external forces affect embryo implantation.

Human Embryo implanting on a 3D platform (video)

Embryo Culture Supplements Development from Human Plasma

Traditionally, embryo culture relied on Human Serum Albumin (HSA) as a key protein component. However, HSA underrepresents the rich composition of proteins present in human plasma. We work with a new-generation of supplements, which go beyond mere albumin, encompassing essential components such as growth factors and globulins, crucial for fostering optimal embryo development. In our group, we test new supplements to enhance embryo development and implantation. Our clinical grade human-derived supplements improve blastulation and implantation rates both in human and mouse embryos, showing superior lineage segregation and spatial organization compared to control counterparts.

The Bioengineering in Reproductive Health is the first Open Innovation Lab research unit at IBEC.

Due to the high translational component of our research, we have established collaboration contracts with the pharma industry, hospitals, and venture capital to bring our technology to the clinics and the market. Our Open Lab is a multidisciplinary environment where embryologists, cell biologists, optical physicists, biophysicists, and business developers synergize to create a unique environment shaped by science and entrepreneurship.

STAFF

PROJECTS

European Projects
HSMe-ImPredict · Development of non-invasive imaging methodology for improving embryo implantation prediction, via hyper-spectral metabolic profiling (2022-2024)Marie Curie Individual FellowshipSamuel Ojosnegros
National projects
HYSPLANT · Selección de embriones para fecundación in vitro: predicción del éxito de implantación mediante clasificación metabólica de embriones (2020-2023)MINECO
Retos investigación: Proyectos I+D
Samuel Ojosnegros
Prediction of implantation success by hyperspectral metabolic profiling of human embryos obtained by in vitro fertilization (2020-2022)AGAUR
Beatriu de Pinós 2018
Samuel Ojosnegros
Private sector
Estudio del mecanismo de acción de OXO-001 (2020-2022)OxolifeSamuel Ojosnegros
Evaluación de derivados plasmáticos humanos para el cultivo de embriones (2019-2021)IVFTECH S.L.Samuel Ojosnegros
Evaluación de derivados plasmáticos humanos para el cultivo de células mesenquimales y CAR-T (2020-2022)IVFTECH S.L.Samuel Ojosnegros
Prediction of implantation success by single-cell transcriptomic profiling of human embryos obtained by in vitro fertilization (2018-2022)Scranton Enterprises BVSamuel Ojosnegros
Finished projects
HYSPLANT · Metabolic profiling of in vitro fertilization embryos using hyspectral imaging (2019-2020)European Commission ATTRACTSamuel Ojosnegros
Embryo on a chip: Smart microdevice development for high-throughput screening embryo implantation (2020)Tecniospring 2020Maria Demestre Viladevall

NEWS

 

HYLIGHT Project, coordinated by Samuel Ojosnegros from IBEC, was selected by the ATTRACT Phase 2, an initiative of the European Union to boost the transfer of deep technology with great potential to transfer from the laboratories to the society. The project was financed with around 2M euros for 26 months and aims to develop a diagnostic device to select embryos based on their metabolic profiles and increase the success rates of in vitro fertilization techniques.

IBEC researchers are part of the European ATTRACT Project to develop a diagnostic device to improve embryo selection for in vitro fertilization procedures

HYLIGHT Project, coordinated by Samuel Ojosnegros from IBEC, was selected by the ATTRACT Phase 2, an initiative of the European Union to boost the transfer of deep technology with great potential to transfer from the laboratories to the society. The project was financed with around 2M euros for 26 months and aims to develop a diagnostic device to select embryos based on their metabolic profiles and increase the success rates of in vitro fertilization techniques.

El projecto REACT, liderado por el Statens Serum Institut de Dinamarca, cuenta con la participación del Instituto de Bioingeniería de Cataluña (IBEC) que, con un presupuesto cercano al millón de euros de un total de siete, generará organoides epiteliales nasales humanos específicos como plataformas de validación y modelos preclínicos para investigar la interacción huésped-patógeno .

El IBEC recibe cerca de un millón de euros para estudiar las enfermedades respiratorias graves causadas por virus

El projecto REACT, liderado por el Statens Serum Institut de Dinamarca, cuenta con la participación del Instituto de Bioingeniería de Cataluña (IBEC) que, con un presupuesto cercano al millón de euros de un total de siete, generará organoides epiteliales nasales humanos específicos como plataformas de validación y modelos preclínicos para investigar la interacción huésped-patógeno .

International experts and three hundred registered attendees met in the 14th IBEC Symposium, dedicated to regenerative therapies. Organised by the Institute for Bioengineering of Catalonia (IBEC), speakers presented the latest advances in mini-organs, organs on a chip, 3D bioprinting and tissue engineering, among others.

14th IBEC Symposium brings international experts and 300 attendees together

International experts and three hundred registered attendees met in the 14th IBEC Symposium, dedicated to regenerative therapies. Organised by the Institute for Bioengineering of Catalonia (IBEC), speakers presented the latest advances in mini-organs, organs on a chip, 3D bioprinting and tissue engineering, among others.

Oxolife, the biotechnological startup focused on the development of drugs to improve female fertility, and the Bioengineering for Reproductive Health laboratory of the Institute for Bioengineering of Catalonia (IBEC), will combine two pioneering technologies for the study and treatment of infertility.

IBEC and Oxolife start a pioneering study to treat infertility

Oxolife, the biotechnological startup focused on the development of drugs to improve female fertility, and the Bioengineering for Reproductive Health laboratory of the Institute for Bioengineering of Catalonia (IBEC), will combine two pioneering technologies for the study and treatment of infertility.

Application Deadline: 15/07/2020Ref: SR-SO The Bioengineering in reproductive health group at the Institute for Bioengineering of Catalonia (IBEC) is looking for a Senior Scientist to develop a project in collaboration with the industry. The project involves investigate the molecular mechanisms affected by specific chemical treatments on endometrial receptivity and on mouse and human embryos in culture. We aim to combine the expertise in microscopy of the lab with embryology tools to understand the morphological and molecular modifications that lead to an increase in endometrial receptivity. An ideal candidate will have experience in the mouse or human embryology field and will know basic tools of molecular biology. The candidate will have a great degree of independence to coordinate the project, competitive salary and funding to outsource several tests (i.e. sequencing, histology etc.). Our laboratory is a multidisciplinary environment where biologists, biophysicists, clinicians and business developers synergize to create a unique environment shaped by science and entrepreneurship. Due to the high translational component of our research, we have established collaboration contracts with the pharma industry, hospitals and venture capital to bring our technology to the clinics and the market. In our lab we use bioengineering methods to create 3D environments that support embryonic development outside of the mother uterus. Our systems are accessible to imaging tools which allow us to interrogate the genetics, metabolomics and mechanics of the embryo in a high throughput manner. Using our systems we are capable to (i) improve embryo culture conditions and (ii) diagnose embryos with improved implantation potential.

Senior researcher at the Bioengineering in Reproductive Health Research Group

Application Deadline: 15/07/2020Ref: SR-SO The Bioengineering in reproductive health group at the Institute for Bioengineering of Catalonia (IBEC) is looking for a Senior Scientist to develop a project in collaboration with the industry. The project involves investigate the molecular mechanisms affected by specific chemical treatments on endometrial receptivity and on mouse and human embryos in culture. We aim to combine the expertise in microscopy of the lab with embryology tools to understand the morphological and molecular modifications that lead to an increase in endometrial receptivity. An ideal candidate will have experience in the mouse or human embryology field and will know basic tools of molecular biology. The candidate will have a great degree of independence to coordinate the project, competitive salary and funding to outsource several tests (i.e. sequencing, histology etc.). Our laboratory is a multidisciplinary environment where biologists, biophysicists, clinicians and business developers synergize to create a unique environment shaped by science and entrepreneurship. Due to the high translational component of our research, we have established collaboration contracts with the pharma industry, hospitals and venture capital to bring our technology to the clinics and the market. In our lab we use bioengineering methods to create 3D environments that support embryonic development outside of the mother uterus. Our systems are accessible to imaging tools which allow us to interrogate the genetics, metabolomics and mechanics of the embryo in a high throughput manner. Using our systems we are capable to (i) improve embryo culture conditions and (ii) diagnose embryos with improved implantation potential.

Application Deadline: 30/06/2020Ref: LT-SO The Bioengineering in Reproductive Health Group offers a lab technician position for an experienced cell culture technician to develop a project in collaboration with the industry. The project involves testing the effects of different cell culture supplements on several cell types (e.g. Mesenchymal Stromal Cells, CAR T Cells, etc.) Our laboratory is a multidisciplinary environment where biologists, biophysicists, clinicians and business developers synergize to create a unique environment shaped by science and entrepreneurship. Due to the high translational component of our research, we have established collaboration contracts with the pharma industry, hospitals and venture capital to bring our technology to the clinics and the market. In our lab, we develop high-tech projects in the fields of embryology, cell biology and imaging. Our strategy involves the development of new products for the pharmaceutical industry. The current position seeks a motivated cell culture technician with experience in diverse cell culture systems.

Cell culture lab technician at the Bioengineering in Reproductive Health Research Group

Application Deadline: 30/06/2020Ref: LT-SO The Bioengineering in Reproductive Health Group offers a lab technician position for an experienced cell culture technician to develop a project in collaboration with the industry. The project involves testing the effects of different cell culture supplements on several cell types (e.g. Mesenchymal Stromal Cells, CAR T Cells, etc.) Our laboratory is a multidisciplinary environment where biologists, biophysicists, clinicians and business developers synergize to create a unique environment shaped by science and entrepreneurship. Due to the high translational component of our research, we have established collaboration contracts with the pharma industry, hospitals and venture capital to bring our technology to the clinics and the market. In our lab, we develop high-tech projects in the fields of embryology, cell biology and imaging. Our strategy involves the development of new products for the pharmaceutical industry. The current position seeks a motivated cell culture technician with experience in diverse cell culture systems.

Santiago Marco, group leader of the Signal and Information Processing for Sensing Systems and Samuel Ojosnegros, Head of Bioengineering in Reproductive Health and have been selected for their research projects in the ATTRACT programme. The call received more than 1200 projects and only 170 proposals were selected. The ATTRACT programme is a pioneering Horizon 2020 research and innovation project funded by the European Union and backed by a consortium of 9 partners. The main objective of this programme is to create a co-innovation ecosystem between fundamental research and industrial communities to develop breakthrough detection and imaging technologies for scientific and commercial uses.

Two projects of the ATTRACT program for IBEC researchers

Santiago Marco, group leader of the Signal and Information Processing for Sensing Systems and Samuel Ojosnegros, Head of Bioengineering in Reproductive Health and have been selected for their research projects in the ATTRACT programme. The call received more than 1200 projects and only 170 proposals were selected. The ATTRACT programme is a pioneering Horizon 2020 research and innovation project funded by the European Union and backed by a consortium of 9 partners. The main objective of this programme is to create a co-innovation ecosystem between fundamental research and industrial communities to develop breakthrough detection and imaging technologies for scientific and commercial uses.

The Institute for Bioengineering of Catalonia (IBEC) has signed an agreement for an initial investment round of one and a half million euros with Scranton Entreprises B.V. -an investment association headquartered in the Netherlands-, with the aim of developing technology that predicts the probability of implantation of embryos obtained through in vitro fertilization. This agreement is the first to be established within the framework of the institute’s new initiative, the Open Innovation Lab, that offers companies and investors a platform to bring the cutting-edge research to patients and to the market faster.

IBEC signs an agreement for 1.5 million euros with Scranton Enterprises

The Institute for Bioengineering of Catalonia (IBEC) has signed an agreement for an initial investment round of one and a half million euros with Scranton Entreprises B.V. -an investment association headquartered in the Netherlands-, with the aim of developing technology that predicts the probability of implantation of embryos obtained through in vitro fertilization. This agreement is the first to be established within the framework of the institute’s new initiative, the Open Innovation Lab, that offers companies and investors a platform to bring the cutting-edge research to patients and to the market faster.

New insights into the intercellular communications mechanism that regulates cell repositioning leads the way towards the development of targeted therapies in regenerative medicine Understanding the language of cells in order to redirect them when necessary: this is one possibility unveiled by researchers at the Center for Regenerative Medicine of Barcelona (CMR[B]), led by Dr. Samuel Ojosnegros, who describe in their latest paper the intercellular communications mechanism involved in cell relocation. The work, published in Proceedings of the National Academy of Sciences (PNAS), was carried out in collaboration with the groups of Elena Martínez (IBEC) and Melike Lakadamyali (ICFO), among others. The fruitful collaboration also gave rise to the publication of work by Verónica Hortigüela, former PhD student in Elena’s group, who bioengineered a nanopatterning strategy that provides control over this communication mechanism.

Deciphering cell language

New insights into the intercellular communications mechanism that regulates cell repositioning leads the way towards the development of targeted therapies in regenerative medicine Understanding the language of cells in order to redirect them when necessary: this is one possibility unveiled by researchers at the Center for Regenerative Medicine of Barcelona (CMR[B]), led by Dr. Samuel Ojosnegros, who describe in their latest paper the intercellular communications mechanism involved in cell relocation. The work, published in Proceedings of the National Academy of Sciences (PNAS), was carried out in collaboration with the groups of Elena Martínez (IBEC) and Melike Lakadamyali (ICFO), among others. The fruitful collaboration also gave rise to the publication of work by Verónica Hortigüela, former PhD student in Elena’s group, who bioengineered a nanopatterning strategy that provides control over this communication mechanism.

JOBS

PUBLICATIONS

S Ojosnegros, A Seriola, AL Godeau, A Veiga (2021) Embryo implantation in the laboratory: an update on current techniques. Human Reproduction Update, Vol.00, No.0, pp. 1–30.

Martin Plöschner, Denitza Denkova, Simone De Camillis, Minakshi Das, Lindsay M. Parker, Xianlin Zheng, Yiqing Lu, Samuel Ojosnegros, and James A. Piper (2020) Simultaneous super-linear excitation-emission and emission depletion allows imaging of upconversion nanoparticles with higher sub-diffraction resolution. Optics Express 28 (16), 24308-24326.

EQUIPMENT

  • Embryo culture laboratory
    • IFV workstations in laminar flow hoods
    • Microscope
    • Micromanipulation-microinjection station
    • Embryo biopsy laser
    • K-systems incubator
  • Cell culture laboratory
    • Biosafety cabinets
    • Incubators
    • Automated cell counter
    • Dry warming/thawing system
    • Sterile tubing welder
    • Tubing sealer
    • Centrifuges
  • Advanced live imaging: photoconversion, 3D imaging, light scattering, spectroscopy
    • Crest spinning disk mounted on a Nikon Ti
    • Image analysis workstation

COLLABORATIONS

  • Prof. Anna Veiga – Barcelona Stem Cell Bank (IDIBELL) and Dexeus Mujer, Barcelona
  • Dr. Montserrat Boada/ Dr. Pere Barri – Dexeus Mujer, Barcelona
  • Dr. Ayelet Lesman – Tel Aviv University (TAU), Israel
  • Dr. Elena Martínez – IBEC
  • Dr. Francesco Cutrale, University of Southern California (USC), USA
  • Dr. Manuel Irimia – CRG, Barcelona
  • Dr. Javier Ramón – IBEC

ENTREPRENEURSHIP

· Jorge Fuentes,
   Business Strategy, A_Ventures, Barcelona, Spain

  

 

Follow us on Twitter: @Biorephealth